About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
Email Alert
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
Email Alert
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-12-30
Henlius Marks Innovation-Driven Milestone with Three Concurrent IND Acceptances
2025-12-30
Henlius Doses First Patient in Phase 1 Trial of Novel PD-1xVEGF Bispecific Antibody HLX37 for Solid Tumors
2025-12-25
Henlius Debuts HLX43 Phase 2 ESCC Data at ASCO GI, Alongside Updates on Serplulimab and Novel Epitope HER2 mAb HLX22
2025-12-23
Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
2025-12-19
U.S. FDA Clearance of IND for Nivolumab Biosimilar HLX18
2025-12-16
Real-World Data of Serplulimab in Small-cell Lung Cancer Patients with Brain Metastases Presented at ESMO IO 2025
2025-12-12
China NMPA Accepts NDA and Grants Priority Review to Serplulimab for Neo-/Adjuvant Treatment of Gastric Cancer
2025-12-10
Henlius Highlights Dual Progress in Breast Cancer Pipeline as HLX11 and HLX78 Data Release at ESMO Asia 2025
2025-12-09
The LATAM Investigator Meeting for the Head-to-Head Trial of HLX22 Versus Pembrolizumab Successfully Held in Brazil
1
2
3
...
51
